Mechanism of decongestant activity of α2-adrenoceptor agonists

被引:38
|
作者
Corboz, M. R. [1 ]
Rivelli, M. A. [1 ]
Mingo, G. G. [1 ]
McLeod, R. L. [1 ]
Varty, L. [1 ]
Jia, Y. [1 ]
Hey, J. A. [1 ]
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
关键词
Decongestants; Pig nasal mucosa; BHT-920; Oxymetazoline; Epinephrine;
D O I
10.1016/j.pupt.2007.06.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The vascular bed in nasal mucosa of different species, including human, is highly vascularized and all extensive sinusoidal network of large capacitance vessels is present deep within the submucosa. When this network of venous sinusoids is engorged with blood, the swollen mucosa reduces the size of the airway lumen and congestion ensues. Nasal vasculature tone is strongly influenced by the sympathetic nervous system and the only drugs approved specifically to relieve vascular nasal obstruction are alpha-adrenoceptor sympathomimetic agents. Due to their vasoconstrictor action, the sympathomimetic decongestants oppose vasodilation, reducing nasal airway resistance and thus facilitating nose breathing. However, standard decongestants that are non-selective a-adrenoceptor agonists are associated with the potential for side-effect liabilities including hypertension, stroke, insomnia and nervousness. We propose than a selective alpha(2)-adrenoceptor agonist, by acting preferentially on nasal venous capacitance vessels, will elicit decongestion with a reduced side-effect liability. In the present study, we evaluated the effects of the selective alpha(2)-adrenoceptor agonist BHT-920 in a real-time tissue contractility assay using isolated pig nasal explants and in an in vivo cat model of congestion. The vasoconstrictor and decongestant effects of BHT-920 were compared to the non-selective alpha-adrenoceptor agonist epinephrine and the standard decongestant oxymetazoline. Our results showed that the alpha(2)-adrenoceptor agonist BHT-920 preferentially contracts venous sinusoids confirming previous observations [Corboz MR, Varty LM, Rivelli MA, Mutter JC, Mingo G, McLeod R., et al. Effects of an alpha(2)-adrenoceptor agonist in nasal mucosa. Arch Physiol Biochem 2003;11: 335-6, Corboz MR, Rivelli MA, Varty LM, Mutter J, Cartwright M, Rizzo CA, et al. Pharmacological characterization of postjunctional alpha-adrenoceptor in human nasal mucosa. Am J Rhinol 2005;19: 495 502] and displays decongestion without affecting blood pressure. Therefore, an alpha(2)-adrenoceptor agonist, by causing constriction in the capacitance vessels of nasal mucosa, can produce nasal decongestion without the effects on blood pressure observed with the standard selective alpha(1)-adrenoceptor and non-selective alpha-adrenoceptor sympathomimetic decongestants. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 50 条
  • [31] Current issues with β2-adrenoceptor agonists -: Pharmacology and molecular and cellular mechanisms
    Anderson, Gary P.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2006, 31 (2-3) : 119 - 130
  • [32] α2-adrenoceptor agonists stimulate high-affinity GTPase activity in a subtype-selective manner
    Pohjanoksa, K
    Jansson, C
    Lang, J
    Wurster, S
    Savola, JM
    Scheinin, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R655 - R655
  • [33] Cardiac implications for the use of β2-adrenoceptor agonists for the management of muscle wasting
    Molenaar, P
    Chen, L
    Parsonage, WA
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 (06) : 583 - 586
  • [34] β2-Adrenoceptor Agonists Are Required for Development of the Asthma Phenotype in a Murine Model
    Thanawala, Vaidehi J.
    Forkuo, Gloria S.
    Al-Sawalha, Nour
    Azzegagh, Zoulikha
    Nguyen, Long P.
    Eriksen, Jason L.
    Tuvim, Michael J.
    Lowder, Thomas W.
    Dickey, Burton F.
    Knoll, Brian J.
    Walker, Julia K. L.
    Bond, Richard A.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2013, 48 (02) : 220 - 229
  • [35] NEW β2-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Schachter, E. N.
    DRUGS OF TODAY, 2010, 46 (12) : 911 - 918
  • [36] β2-adrenoceptor agonists as potential therapeutic drugs in diabetic peripheral neuropathy
    Baraka, A. M.
    Darwish, I. E.
    Ghoneim, M. T.
    Korayem, H. K.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 746 : 89 - 95
  • [37] Understanding of the Enhancement of Glucocorticoid-Dependent Transcription by β2-Adrenoceptor Agonists
    Rider, C. F.
    Giembycz, M.
    Newton, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [38] Long-acting β2-adrenoceptor agonists:: a smart choice for asthma?
    Lipworth, Brian J.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (06) : 257 - 262
  • [39] Mechanism of the vascular angiotensin II/α2-adrenoceptor interaction
    Jackson, EK
    Gao, LP
    Zhu, CX
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (03): : 1109 - 1116
  • [40] Effects of some imidazolidine α2-adrenoceptor agonists in rat isolated atria
    Thaina, P
    Nott, MW
    Rand, MJ
    JOURNAL OF AUTONOMIC PHARMACOLOGY, 1999, 19 (03): : 185 - 191